Arletta Pharma Secures FDA Endorsement for Lybrido Phase 2 Program, Eyes Streamlined Path to NDA for Female Sexual Interest/Arousal Disorder
核心洞察
The FDA endorsed key elements of Arletta Pharma's proposed Phase 2 MONARCH dose-ranging study for Lybrido, including a single primary endpoint focused on sexual desire.
The Agency expressed openness to a single pivotal Phase 3 study combined with confirmatory evidence to support a future New Drug Application for FSIAD and HSDD.
Lybrido is an on-demand, dual-action therapy combining sublingual testosterone with a sildenafil inner core, targeting both psychological and physiological components of female sexual disorders.
The United States Food and Drug Administration has provided a written response to Arletta Pharma Solutions (搜索)' Type C meeting request that endorses core elements of the proposed Phase 2 MONARCH study for Lybrido, the company's lead investigational therapy for Female Sexual Interest/Arousal Disorder (搜索) (FSIAD) and Hypoactive Sexual Desire Disorder (搜索) (HSDD). In its response, the FDA confirmed that the proposed doses and treatment duration appear reasonable and that a single primary endpoint focused on sexual desire is acceptable. The Agency also expressed openness to Arletta's strategy of relying on a single pivotal Phase 3 study in the United States to support a future New Drug Application, in combination with confirmatory evidence from the company's broader development program.
"The FDA's feedback represents a significant validation of our development strategy and an important step forward for Arletta Pharma," said Steve van Os, Chief Medical Officer of Arletta Pharma Solutions (搜索). "The Agency's endorsement of key aspects of our proposed Phase 2 MONARCH study, combined with its openness to a streamlined path to NDA submission based on a single pivotal Phase 3 trial, provides a clear framework for our U.S. development program."
The FDA's response follows a comprehensive Type C meeting package submitted by Arletta and reflects continued engagement between the company and the Agency's Division of Urology, Obstetrics, and Gynecology. As is customary at this stage of development, the FDA also identified areas where refinements are requested, including elements of study design, statistical approach, and safety characterization. Arletta considers these observations constructive and consistent with expectations.
A Dual-Action Mechanism in an Evolving Regulatory Landscape
Lybrido is an investigational on-demand, dual-action therapy consisting of a novel dual-route, dual-release, fixed-dose combination tablet with a testosterone coating for sublingual administration and an inner-core component containing the PDE5 (搜索) inhibitor sildenafil. The proprietary delayed-immediate-release formulation is designed so that the peak plasma concentration of sildenafil coincides with the window of increased sexual motivation induced by sublingually administered testosterone, with effects lasting 3 to 6 hours after intake.
This dual-action mechanism distinguishes Lybrido from the two FDA-approved options currently on the market: flibanserin (Addyi), approved in 2015 for premenopausal women with HSDD, which acts centrally as a serotonin receptor agonist and dopamine agonist taken daily, and bremelanotide (Vyleesi), a melanocortin receptor agonist administered by injection. A fixed-dose dual-release oral tablet used on demand occupies a different pharmacological and practical position than either existing therapy.
The FDA's response arrives at a time when the Agency has shown increasing openness toward the use of hormone therapy and testosterone in women, an evolution that directly supports Lybrido's testosterone-containing formulation. This posture shift is notable given that off-label testosterone use for female sexual dysfunction has long outpaced regulatory clarity.
Streamlined Regulatory Pathway
The FDA recently formalized a single-trial pathway as its default standard for new drug approvals, pairing one well-controlled pivotal study with confirmatory evidence. Arletta's program is now explicitly structured around that framework, which reduces both capital exposure and development time without requiring a waiver or special accommodation.
The positive tone of the FDA feedback comes alongside recently reported positive Phase II Clitoral Doppler Duplex Ultrasound results for Lybrido, providing the program with an objective hemodynamic signal alongside subjective desire data. To date, Lybrido has been investigated in 20 Phase 1 and Phase 2a trials, plus large-scale Phase 2b studies conducted across 17 US research sites, establishing a substantial safety and efficacy database.
Next Steps
The company is currently finalizing preparations for the Phase 2 MONARCH dose-ranging study (FPS203). The primary endpoint responder rate in MONARCH's dose-ranging arms will be the critical metric to watch, as FDA has accepted a sexual desire-focused primary endpoint. A robust desire signal in MONARCH would lock in the most efficient route to an NDA; a weak signal would necessitate a redesign. Arletta is advancing Lybrido's late-stage development on parallel tracks in Europe and the United States.